Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
Avalo’s phase 2 win fuels AbbVie chase despite placebo headwind
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival drug, but the biotech’s stock rose in premarket trading.
Nick Paul Taylor
May 6, 2026 6:00am
Windward breezes toward phase 3 with $165M for TSLP ambitions
May 4, 2026 10:31am
Lipella goes bankrupt, ending mouth inflammation drug ambitions
Mar 31, 2026 7:20am
After $1B fundraise, Xaira breaks silence on AI work
Mar 17, 2026 2:52pm
MoonLake arthritis win kicks off pivotal year for IL-17 nanobody
Feb 23, 2026 5:10am
Rasayana Tx ingests GI candidate in $36M deal
Feb 18, 2026 10:40am
